Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
For the estimated 5 million people in the United States with AF, several treatment approaches are used, each with a wide range of pharmacological options. The established guidelines recommend the use of rate control and rhythm control strategies to establish a normal sinus rhythm, accompanied by use of antithrombotic therapy for stroke risk reduction. This report provides a quantitative analysis of treatment patterns and patient share by line of therapy as well as progression between lines, duration of treatment, and use of concomitant treatment for newly diagnosed AF patients. It also quantifies a drug’s source of business and details which drugs precede others through an analysis of add-versus-switch patterns for recently treated patients. Additional analyses explore persistency and compliancy by brand.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Boehringer Ingelheim.
Key drugs: Xarelto, Eliquis, Savaysa, Pradaxa, warfarin, amiodarone, metoprolol.
Key analysis provided:
Already a Client? Log in to access this report.
Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.